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Abstract
The quinazoline scaffold is found in the chemical structure of many marketed 
drugs used in CNS disorders as antidepressants, anxiolytics, or hypnotics. Also, the 
carbamate ester derivatives have different certain therapeutic actions, such as hyp-
notic or parasympathomimetic ones. We have obtained new 4(3H)-quinazolinones 
by bringing together in the same structure the quinazoline nucleus and carbamate 
ester group. The compounds named Q1–Q5 were characterized by measuring the 
melting points, by determining the infrared and NMR spectra, and by elemental 
analysis. The pharmacological tests evidenced that the compounds have a very low 
acute toxicity, lethal doses being >2000 mg/kg bw. The compounds had different 
actions observed in forced swimming test (FST), tail suspension test (TST), or 
elevated plus maze (EPM), probably influenced by the presence of different radi-
cals on the nucleus. Thus, Q1 with a nitro group in structure manifested the highest 
antidepressant effect, showing a reduction of immobilization time in FST and 
TST. On the other hand, Q3 and Q5, with two groups methoxy, respective ethoxy, 
had a slight anxiolytic effect, highlighted by an increase of the time spent in open 
arms and a decrease of the time spent in closed arms of EPM.
Keywords: quinazolines, synthesis, antidepressant, anxiolytic, forced swimming 
test, tail suspension test, elevated plus maze
1. Introduction
The quinazolines constitute an important class of fused heterocycles that are 
also known as 5,6-benzopyrimidine or benzo[a]pyrimidine, benzo-1,3-diazine, 
or 1,3-diazanaphthalene. The name quinazoline was first proposed for this com-
pound by Weddige, due to the similarity with cinnoline and quinoxaline [1, 2]. 
The 4-hydroxyquinazolines, tautomeric with 4-keto-3,4-dihydroquinazolines, are 
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commonly named 4(3H)-quinazolones; they are an important class of heterocyclic 
compounds, more than 200 natural compounds having this basic structure [3].
The stability of the quinazolinone nucleus was an important reason why many 
drug chemistry studies followed synthesis in this class of compounds; a large num-
ber of compounds have been synthesized and evaluated for their different biologi-
cal activities. The first renowned quinazoline marketed drug was methaqualone, 
used for its sedative-hypnotic effects since 1951 [4].
The quinazoline scaffold is found in the chemical structure of many marketed 
drugs used in CNS disorders, having antidepressant, hypnotic, and sedative effect 
(afloqualone, diproqualone, etaqualone, and methaqualone), or used as anticon-
vulsant (piriqualone), antipyretic, nonsteroidal anti-inflammatory (fluproquazone 
and proquazone), and antidiabetic agents (balaglitazone, raltitrexed, ispinesib, and 
halofuginone) [5].
The anticonvulsant action of these compounds has become a priority for 
pharmacological testing [2], many of these studies highlighting the importance of 
methyl group at the second position of quinazolin-4(3H)-one [6]. As Gatadi et al. 
have also shown, more and more recent studies are concerned with investigating 
the antimicrobial potential of quinazolone derivatives because bacterial strains have 
developed resistance to available chemotherapeutics [7].
Several research groups have successfully investigated and reported the promis-
ing antimicrobial properties and structure-activity relationships (SAR) of various 
4(3H)-quinazolinone derivatives [8, 9].
As Hieu et al. reported in recent studies, novel hydroxamic acids incorporating 
quinazoline-4(3H)-one are a promising class of molecules of interest for the treat-
ment of cancer [10, 11].
On the other hand, it is known that the carbamate ester derivatives have dif-
ferent certain therapeutic actions; this class includes physostigmine, neostigmine, 
pyridostigmine, rivastigmine, methocarbamol, and carisoprodol.
Carbamates are also of interest for their action as HIV-1 protease inhibitors 
(darunavir, amprenavir, and atazanavir) [12].
We have concentrated our research activity on bringing together the quinazoline 
nucleus and carbamate ester group in the same 4(3H)-quinazolinone structure [13].
2. Synthesis of 4(3H)-quinazolinone derivatives
We obtained the new 4(3H)-quinazolone derivatives using the acylation of 
potassium 2-[2-methyl-3-(4-oxoquinazolin-3(4H)-yl)-aceto]-hydroxamate with 
aromatic acid chlorides in the presence of dioxane [14]. The general reaction 
scheme is presented (Figure 1).
We obtained the new derivatives by applying the following working technique:
Around 0.68 g (0.0025 mol) of potassium 2-[2-methyl-3-(4-oxoquinazolin-
3(4H)-yl)-aceto]-hydroxamate was heating, and then 0.0025 moles of acid chloride 
in 20 mL of dioxane was gradually added; a white precipitate (potassium chloride) 
Figure 1. 
The synthesis of new 4(3H)-quinazolinone derivatives.
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is formed. The reaction mixture is refluxed for 3 hours and then filtered. The filtrate 
was evaporated to dryness by mild heating under vacuum to give the crude product. 
The new compounds are recrystallized from isopropanol.
All chemicals and solvents were supplied by Sigma-Aldrich Chemical Company. 
All the solvents were distilled and dried before use.
Melting points were measured in open capillary tubes on an Electrothermal 9100 
apparatus, and they are uncorrected.
Infrared spectra were recorded on a FT/IR-solid in ATR spectrometer (the 
signal intensities (height) were denoted by the following abbreviations: w = weak, 
m = medium, s = strong, v = variable).
The NMR spectra were recorded on a Varian 2000 and Bruker Fourier 300 
instruments at room temperature, operating at 300 MHz for 1H and 75 MHz for 
13C. The chemical shifts were recorded in δ units (ppm), relative to residual peak 
of the deuterated dimethyl sulfoxide (DMSO-d6). Tetramethylsilane (TMS) was 
used as internal standard. The coupling constants values are reported in hertz, and 
the splitting patterns are abbreviated as follows: s = singlet, d = doublet, t = triplet, 
m = multiplet, and b = broad.
The elemental analyses were performed on a PerkinElmer CHNS/O Analyzer 
Series II 2400 apparatus, and the results were in agreement with the calculated values.
For a better interpretation of spectral data, we used the numbering of the atoms 
presented in Table 1.
Compound Q1: 3-(4-Nitro-phenyl-carbonyl-oxi-carbamoyl-methyl) 
-2-methylquinazolin-4(3H)-one.
C18H14N4O6 (Mr 382.33); m.p. 183–184°C; yield 38.7%.
Elemental analysis: Calculated: C 56.55%, H 3.69%, N 14.65%; found: C 56.78%, 
H 3.56%, N 14.84%.
1H-NMR (dmso-d6, δ ppm, J Hz, T = 308 K): 12.84(s, 1H, H-12); 8.39 
(d, 2H, H-16, H-18, J = 9.4); 8.27(d, 2H, H-15, H-16, J = 9.2); 8.11(dd, 1H, H-5, 
J = 7.8, J = 1.6); 7.82(td, 1H, H-7, J = 7.8, J = 1.6); 7.61(bd, 1H, H-8, J = 7.8); 7.51 
(td, 1H, H-6, J = 7.8, J = 1.4); 4.98(s, 2H, H-10); 2.58(s, 3H, H-9).
13C-NMR (dmso-d6, δ ppm, T = 308 K): 164.99(CO-11); 162.69(CO-13); 
161.13(C-4); 155.11(C-2); 150.87(C-17); 146.97(C-1a); 131.86(C-14); 119.57(C-4a); 
134.71(C-7); 131.13(C-16, C-18); 126.60(C-8); 126.56(C-6); 126.28(C-5); 124.26(C-
15, C-19); 43.96(C-10); 22.73(C-9).
FT-IR (solid in ATR, ν cm−1): 3164 m; 3077w; 3017w; 2976 m; 1783s; 1711 m; 
1642vs; 1597vs; 1528vs; 1473 m; 1416w; 1386w; 1347s; 1233 m; 1066 m; 975 m; 
873w; 844w; 774 m; 710 m; 658w.
Compound Q2: 3-(3-Methyl-phenyl-carbonyl-oxi-carbamoyl-methyl) 
-2-methylquinazolin-4(3H)-one.
C19H17N3O4 (Mr 351.36); m.p. 151–52°C, yield 42.5%.
Elemental analysis: Calculated: C 64.95%, H 4.88%, N 11.96%; found 64.80%, 
H 4.85%, N 12.04%.
1H-NMR (dmso-d6, δ ppm, J Hz, T = 308 K): 12.61(s, 1H, H-12); 8.11(dd, 1H, 
H-5, 1.4, 8.0); 7.85(t, 1H, H-15,); 7.82(td, H-7, 8.0, 1.4); 7.85÷7.80(m, 2H, H-15, 
H-19); 7.62(dd, 1H, H-8, 1.4, 8.0); 7.56(bd, 1H, H-17, 7.7); 7.51(td, 1H, H-6, 8.0, 1.4); 
7.47(t, 1H, H-18, 7.7); 4.97(s, 2H, H-10); 2.58(s, 3H, H-9); 2.38(s, 3H, H-16′).
13C-NMR (dmso-d6, δ ppm, T = 308 K): 164.86(CO-11); 164.14(CO-
13); 161.14(C-4); 155.17(C-2); 147.00(C-1a); 138.78(C-16); 126.42(C-14); 
119.61(C-4a);135.18(C-19); 134.70(C-7); 129.85(C-15); 129.10(C-17); 126.73(C-18); 
126.60(C-8); 126.55(C-6); 126.30(C-5); 43.94(C-10); 22.73(C-9); 20.73(C-16′).
FT-IR (solid in ATR, ν cm−1): 3200 m; 3004w; 2956w; 1774 m; 1672vs; 1599s; 
1519w; 1468 m; 1385 m; 1340w; 1264 m; 1170 m; 1065 m; 972 m; 860w; 778 m; 
733 m; 695w.
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Compound Q3: 3-(3,5-Dimethoxy-phenyl-carbonyl-oxi-carbamoyl-methyl)-2-
methylquinazolin-4(3H)-one.
C20H19N3O6 (Mr 397.39); m.p. 148–49°C, yield 48.1%.
Elemental analysis: Calculated: C 60.45%, H 4.82%, N 10.57%; found C 60.60%, 
H 4.96%, N 10.65%.
1H-NMR (dmso-d6, δ ppm, J Hz, T = 308 K): 12.58(s, 1H, H-12); 8.10(dd, 
1H, H-5, J = 7.8 Hz, J = 1.6 Hz); 7.79(td, 1H, H-7, J = 7.8, J = 1.6); 7.62(bd, 1H, H-8, 
J = 7.8); 7.51(td, 1H, H-6, J = 7.8, J = 1.5); 7.11(d, 2H, H-15, H-19, J = 2.3); 6.87 
(t, 1H, H-17, J = 2.3); 4.96(s, 2H, H-10); 3.81(s, 6H, H-16′, H-18′); 2.58(s, 3H, H-9).
13C-NMR (dmso-d6, δ ppm, T = 308 K): 164.86(CO-11); 163.74(CO-13); 
161.13(C-4); 160.69(C-16, C-18); 155.09(C-2); 147.05(C-1a); 128.33(C-14); 
119.61(C-4a); 134.65(C-7); 126.63(C-8); 126.51(C-6); 126.26(C-5); 106.99(C-19, 
C-15); 106.46(C-17); 55.66(C-16′, C-18′); 43.93(C-10); 22.73(C-9).
Table 1. 
Numbering of atoms for spectral interpretation.
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FT-IR (solid in ATR, ν cm−1): 3239w; 3092w; 2949w; 2844w; 1775 m; 1676vs; 
1600vs; 1500w; 1469 m; 1431 m; 1390 m; 1352 m; 1305 m; 1212 m; 1195 m; 1179 m; 
1165 m; 1081w; 1051 m; 1016 m; 976 m; 931w; 877w; 848w; 772 m; 747w.
Compound Q4: 3-(3,4,5-Trimethoxy-phenyl-carbonyl-oxi-carbamoyl-methyl)-
2-methylquinazolin-4(3H)-one.
C21H21N3O7 (Mr 427.41); m.p.152–53°C, yield 45.3%.
Elemental analysis: Calculated: C 59.01%, H 4.95%, N 9.83%; found C 58.92%, 
H 5.05%, N 10.02%.
1H-NMR (dmso-d6, δ ppm, J Hz, T = 308 K): 12.58(s, 1H, H-12); 8.11(dd, 1H, 
H-5, J = 7.3, J = 1.6); 7.82(td, 1H, H-7, J = 7.3, J = 1.6); 7.62(bd, 1H, H-8, J = 7.3); 
7.51(td, 1H, H-6, J = 7.3, J = 1.4); 7.29(s, 2H, H-15, H-19); 4.96(s, 2H, H-10); 3.85 
(s, 6H, H-16′, H-18′); 3.76(s, 3H, H-17′); 2.58(s, 3H, H-9).
13C-NMR (dmso-d6, δ ppm, T = 308 K): 164.88(CO-11); 163.64(CO-13); 
161.13(C-4); 155.10(C-1a); 152.99(C-16, C-18); 147.05(C-17); 142.69(C-14); 
121.30(C-14); 119.61(C-4a); 134.65(C-7); 126.63(C-8); 126.51(C-6); 126.26 
(C-5); 106.83(C-15, C-19); 60.25(C-17′); 56.13(C-16′, C-18′); 43.90(C-10); 
22.72(C-9).
FT-IR (solid in ATR, ν cm−1): 3200 w; 2979 w; 1766 m; 1680 vs; 1601 s; 1512 m; 
1465 m; 1416 wm; 1405 w; 1277 m; 1250 m; 1209 m; 1188 m; 1144 m; 1071 m; 
1017 m; 972 m; 870 m; 772 m.
Compound Q5: 3-(3,5-Diethoxy-phenyl-carbonyl-oxi-carbamoyl-methyl)-2-
methylquinazolin-4(3H)-one.
C22H23N3O6 (Mr 425.44); m.p. 158–59°C, yield 35.8%.
Elemental analysis: Calculated: C 62.11%, H 5.45%, N 9.88%; found C 62.25%, 
H 5.58%, N 10.05%; m.p. 158–159°C; yield 35.8%.
1H-NMR (dmso-d6, δ ppm, J Hz, T = 308 K): 12.59(s, 1H, H-12); 8.11(dd, 1H, 
H-5, J = 7.8, J = 1.6); 7.82(td, 1H, H-7, J = 7.8, J = 1.6); 7.62(bd, 1H, H-8, J = 7.8); 
7.51(td, 1H, H-6, J = 7.8, J = 1.4); 7.07(d, 2H, H-15, H-19, J = 2.1); 6.82(t, 1H, H-17, 
J = 2.1); 4.96(s, 2H, H-10); 4.07(q, 4H(CH2), H-16′, H-18′, J = 6.9); 2.58(s, 3H, H-9); 
1.32(t, 6H(CH3), H-16′, H-18′, J = 6.9).
13C-NMR (dmso-d6, δ ppm, T = 308 K): 163.78(CO-11); 163.14(CO-13); 
161.09(C-4); 159.88(C-16, C-18); 155.03(C-2); 147.01(C-1a); 128.25(C-14); 
119.57(C-4a).
134.58(C-7); 126.58(C-8); 126.44(C-6); 126.20(C-5); 107.30(C-16, C-18); 
107.21(C-17); 63.64(CH2-16′, CH2-18′); 43.89(C-10); 22.67(C-9); 14.43(CH3-16′’, 
CH3-18′).
FT-IR (solid in ATR, ν cm−1): 3219 w; 2980 w; 2937 w; 2882 w; 1778 m; 
1675 vs; 1602 s; 1510 w; 1471 w; 1451 m; 1389 m; 1372 m; 1355 m; 1301 m; 1179  
vs; 1116 m; 1086 m; 1058 s; 976 m; 934 m; 859 m; 829 w; 776 m; 747 m; 708 w; 
692 w; 676 w; 658 m.
3. Pharmacological research on new 4(3H)-quinazolinone derivatives
3.1 Objective
The main objective of our study was to assess the potential pharmacological 
actions on central nervous system of five new 4(3H)-quinazolinone derivatives. For 
this purpose, we evaluated first the acute oral toxicity on mice, using the “up and 
down” method, in accordance with European Guidelines regarding the ethic  
of experimental research on animals [15]. These guides mention that the sub-
stances expected to have a low degree of toxicity can be tested using the limit test 
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at 2000 mg/kg bw and only in special situations at the dose of 5000 mg/kg bw. 
After assessing the toxicity level of the substances, we performed a battery of tests 
to highlight the pharmacological potential of the new compounds on the central 
nervous system. Thus, we determined the antidepressant effect using the forced 
swimming test (FST) and tail suspension test (TST); the effect on anxiety using the 
elevated plus maze (EPM), Ugo Basile, Italy; and the effect on the motor activity 
with the activity cage (Ugo Basile).
All pharmacological tests were performed on mice, following all the existing 
protocols from the Laboratory of Pharmacology, Faculty of Pharmacy, UMF “Carol 
Davila” Bucharest.
3.2 Materials and methods
We used for the pharmacological experiments 85 male, white, NMRI mice, 
weighing 26 ± 1.7 g. The animals were supplied by the rodent farm of the University 
of Medicine and Pharmacy “Carol Davila” Bucharest. The animals were housed in 
ventilated cages with free access to food and water. The temperature and the relative 
humidity were kept constant (22–24°C, 45–60%).
All experimental procedures were carried out in accordance with the Directive 
2010/63/UE of 22 September 2010, regarding the protection of animals used for 
experimental and other scientific purposes. All experimental procedures were 
approved by the Ethical Committee of the Faculty of Pharmacy, Bucharest. The 
experiment was conducted in May 2018.
For acute toxicity evaluation, we used five groups of three mice each, which 
received the new five quinazolinone derivatives in the dose of 2000 mg/kg bw p.o. 
All animals were followed for 14 days regarding any sign of lethality, body weight 
evolution, or behavior changes.
The pharmacological tests on central nervous system were performed on 
70 mice, which were initially subjected to the Ugo Basile activity cage test. The 
parameter on which the animals were divided into groups was the horizontal motor 
activity, measured for every period of 5 min. The mice were divided into 7 groups 
of 10 individuals each, with similar average responses and standard deviations 
between groups.
The compounds were administered as shown below:
• Group I (control)—distilled water 0.1 ml/10 g orally
• Group II (reference)—amitriptyline 10 mg/kg bw susp. 0.1% orally
• Group III—Q1 100 mg/kg bw, susp. 1% orally
• Group IV—Q2 100 mg/kg bw, susp. 1% orally
• Group V—Q3 100 mg/kg bw, susp. 1% orally
• Group VI—Q4 100 mg/kg bw, susp. 1% orally
• Group VII—Q5 100 mg/kg bw, susp. 1% orally
We decided to test the animals at a dose of 100 mg/kg bw, considering the level 
of 1/20 of the dose administered in acute toxicity test which provided no lethal 
effects to mice.
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The pharmacological tests were performed as follows:
• After 1 day of administration: activity cage and FST
• After 14 days of administration: activity cage and TST
• After 15 days of administration: EPM
FST was chosen after acute administration because it proved effective and 
consistent in testing antidepressant effect after one single dose [16].
All tests were conducted respecting the following protocol: in the testing cham-
ber, the animals were kept in artificial light. Each individual was administered with 
a 7-min delay from the previous one (5 min for the test itself and 2 min to clean the 
device before testing the next animal) so that all of them could be tested after the 
same time interval from the moment of receiving the treatment.
Determination of motor activity assessed the influence of new compounds on 
mice motility and desire to explore. The duration of this test in the activity cage was 
5 min for each mouse. The animals were placed each time in the same corner of the 
device [17].
Determination of immobility time of mice in forced swimming test (FST), was 
originally described by Porsolt [16, 18]. Each mouse was placed into a glass cylinder 
(25 cm height, 30 cm diameter) containing water at a temperature of 23 ± 1°C. The 
test duration was 6 min, the first two for accommodation and the next four for the 
actual determination of the immobilization time. The mouse is considered immobi-
lized when it ceases to struggle and remains in an immobile, characteristic position, 
with minimal movements for keeping the head above the water.
Determination of immobility time of mice in tail suspension test (TST) involves 
the same principle as FST, the difference being the nature of the inducing factor of 
the depressive state, the suspension of the animal by the tail. In this test, there is no 
need for accommodation, so the determination of the immobility time starts from 
the beginning of the experiment [19].
Determination of anxiolytic potential of the compounds was performed using the 
elevated plus maze Ugo Basile. The mouse was placed in the center of the device, and 
it was left free to explore the maze. We determined the time spent into the open 
arms and the time spent into the closed arms. We considered that the mouse was in 
one of the arms when all four limbs were in that arm [20].
3.2.1 Statistical analysis
Statistical calculation used the software GraphPad Prism version 8.0.0 for 
Windows, GraphPad Software, San Diego, California, USA, www.graphpad.com. 
Statistical comparison between groups used the ANOVA test. In case it indicated 
a statistical significance, the Tukey posttest was performed comparing all groups 
2 × 2. When appropriate, we determined the Pearson correlation coefficient.
Normality of response distribution in collectivity was tested with D’Agostino 
and Pearson test.
3.3 Results and discussion
Acute toxicity research did not lead to any lethality for the five new compounds 
administered at a dose of 2000 mg/kg bw. According to the “up and down” method, 
higher doses are not recommended, and the compounds can be classified in the 
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category “very low toxicity.” Evolution of body weight, determined every other day 
for 14 days, was similar between treated mice and control ones. Changes in weight 
were small, being statistically insignificant. Motor behavior was similar, and response 
to auditory and tactile stimuli was present. No animal showed any palpebral ptosis, 
and the appearance of the fur and tail remained unchanged during the experiment.
After the initial determination of motor activity, the mice were divided into 
seven homogenous groups, each containing 10 individuals. Their baseline mean 
horizontal motor activity is shown in Table 2, and the Gaussian distribution of the 
individual results is highlighted in Figure 2:
After acute administration, compound Q5 had the most intense effect on motor 
activity, with a 23.69% reduction in HMA compared with the control group. This 
result was statistically significant according to ANOVA followed by Tukey posttest. 
The same compound reduced VMA with 37.39% compared with the control, but 
this result was not significant. Q3 was another compound which reduced the motor 
activity by more than 20%, but the results were not significant. The other three 
new quinazolinones had limited influence on motor activity. Amitriptyline used as 
the reference substance did not influence significantly the motor activity after one 
administration, as it can be observed in Tables 3 and 4.
The immobilization time in FST after acute administration was influenced 
differently by the new five compounds and was correlated with the results obtained 
in motor activity testing. In Table 5, it can be seen that compounds that have 
decreased the most intense motor activity (Q3, Q5) have led to an increase in 
immobilization time, with 44.09 and 41.24% compared with the reference group. 
Compound Q1 had the most intense antidepressant effect after one dose, quantified 
by reducing the immobilization time with 20.39% compared with the control group.
Figure 2. 
Normal distribution of initial HMA values.
Group I Group II Group III Group IV Group V Group VI Group VII
M 623.2 622.1 623.5 622.6 623.0 622.8 623.9
SD 100.7 104.1 86.1 107.7 95.25 99.29 107.52
M = average, SD = standard deviation.
Table 2. 
The horizontal motor activity (HMA) of the groups formed after the selection process.
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M ± SD ANOVA Effect % vs. 
control
Tukey posttest/
control
Effect % vs. 
reference
Tukey 
posttest/
reference
Group I 
(control)
500.50 ± 91.25 <0.001** — — — —
Group II 
(reference)
477.50 ± 80.27 −4.59% ns — —
Group III (Q1) 499.00 ± 46.82 −0.29% ns −4.50% ns
Group IV (Q2) 472.50 ± 57.33 −5.59% ns −1.05% ns
Group V (Q3) 398.50 ± 52.26 −20.37% ns −16.54% ns
Group VI (Q4) 436.50 ± 107.1 −12.78% ns −8.58% ns
Group VII (Q5) 381.90 ± 107.0 −23.69% <0.05* −20.02% ns
*Statistical significance
**High statistical significance
Table 3. 
The horizontal motor activity (HMA) of the groups after one administration.
M ± SD ANOVA Effect % vs. 
control
Effect % vs. 
reference
Group I (control) 59.90 ± 26.94 ns — —
Group II (reference) 50.90 ± 15.59 −15.02% —
Group III (Q1) 50.70 ± 14.21 −15.35% −0.39%
Group IV (Q2) 52.50 ± 19.73 −12.35% −3.14%
Group V (Q3) 45.50 ± 15.38 −24.04% −10.60%
Group VI (Q4) 46.30 ± 17.01 −22.70% −9.03%
Group VII (Q5) 37.50 ± 28.16 −37.39% −26.33%
Table 4. 
The vertical motor activity (VMA) of the groups after one administration.
M ± SD ANOVA Effect % 
vs. control
Tukey 
posttest/
control
Effect % vs. 
reference
Tukey posttest/
reference
Group I 
(control)
121.10 ± 34.51 <0.0001*** — — — —
Group II 
(reference)
98.20 ± 18.97 −18.91% ns — —
Group III (Q1) 96.40 ± 14.47 −20.39% ns −1.83% ns
Group IV (Q2) 101.30 ± 16.40 −16.35% ns 3.15% ns
Group V (Q3) 138.70 ± 28.13 14.53% ns 41.24% <0.01**
Group VI (Q4) 132.70 ± 26.03 9.57% ns 35.13% <0.05*
Group VII (Q5) 141.50 ± 27.73 16.84% ns 44.09% <0.01**
*Statistical significance.
**High statistical significance.
***Statistical significance. Very high statistical significance.
Table 5. 
The immobilization time in FST after one administration.
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It was interesting to find the degree of Pearson correlation between the values 
obtained in the two tests after acute administration. As it can be observed in 
Figure 3, the best correlation of data is between values of group Q5—HMA and 
FST—with a coefficient of −0.622.
After 2 weeks of daily administration, the motor activity of the mice has illus-
trated a significant reduction of HMA in Q5 group, with 22.48% compared with 
control, which can be seen in Table 6. Also, in accordance with the known fact 
that amitriptyline has a sedative pharmacological profile, it determined a marked 
decrease of horizontal movements, with 18.79% compared with control.
Regarding the vertical movements, amitriptyline and the new compounds Q3 
and Q5 produced the largest decrease, with effects between 14.63 and 34.03%, but 
ANOVA showed no statistical significance (Table 7).
Figure 3. 
Pearson correlation between data obtained in activity cage test and forced swimming test after acute 
administration (black circle—the best correlation for a compound between immobilization time in FST and 
horizontal movements activity).
M ± SD ANOVA Effect % 
vs. control
Tukey posttest/
control
Effect % vs. 
reference
Tukey posttest/
reference
Group I (control) 471.50 ± 72.75 <0.0001*** — — — —
Group II 
(reference)
382.90 ± 64.70 −18.79% <0.05* — —
Group III (Q1) 479.50 ± 65.91 1.69% ns 25.22% <0.05*
Group IV (Q2) 482.50 ± 72.71 2.33% ns 26.01% <0.05*
Group V (Q3) 404.30 ± 50.62 −14.25% ns 5.58% ns
Group VI (Q4) 468.30 ± 56.68 −0.67% ns 22.30% ns
Group VII (Q5) 365.50 ± 52.63 −22.48% <0.01** −4.54% ns
*Statistical significance.
**High statistical significance.
***Very high statistical significance.
Table 6. 
The horizontal motor activity (HMA) of the groups after 14 days of administration.
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Tail suspension test after 14 days of administration evidenced the compound Q1 
which reduced the immobilization time with 20.13% compared with control. The 
effect is comparable to that of the reference substance. Compound Q5 produced an 
increase of immobilization time, with 3.66% compared with control and 28.70% 
compared with amitriptyline (Table 8).
M ± SD ANOVA Effect % vs. control Effect % vs. reference
Group I (control) 56.70 ± 17.13 ns — —
Group II (reference) 47.40 ± 16.53 −16.40% —
Group III (Q1) 59.00 ± 14.79 4.05% 24.47%
Group IV (Q2) 51.10 ± 17.99 −9.87% 7.80%
Group V (Q3) 48.40 ± 10.99 −14.63% 2.10%
Group VI (Q4) 51.80 ± 14.48 −8.64% 9.28%
Group VII (Q5) 37.40 ± 15.58 −34.03% −21.09%
Table 7. 
The vertical motor activity (VMA) of the groups after 14 days of administration.
M ± SD ANOVA Effect % vs. 
control
Tukey posttest/
control
Effect % vs. 
reference
Tukey posttest/
reference
Group I (control) 103.80 ± 14.81 <0.01** — — — —
Group II 
(reference)
83.60 ± 14.67 −19.46% ns — —
Group III (Q1) 82.90 ± 12.16 −20.13% ns −0.83% ns
Group IV (Q2) 94.10 ± 14.62 −9.34% ns 12.55% ns
Group V (Q3) 104.20 ± 18.61 0.38% ns 24.64% ns
Group VI (Q4) 96.20 ± 19.86 −7.32% ns 15.07% ns
Group VII (Q5) 107.60 ± 22.46 3.66% ns 28.70% <0.05*
*High statistical significance Statistical significance
**Statistical significance.
Table 8. 
The immobilization time in TST after 14 days of administration.
Figure 4. 
Time in open arms of EPM after 15 days of administration (the columns represent the mean + SD).
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At the end of the experiment, we wanted to see if the new quinazolinones had 
any influence on the anxious natural behavior of the mice. It is well known that 
placed in the plus maze, mice prefer to explore closed and secure arms instead of 
open ones, associated with imminent danger. The results in elevated plus maze 
test evidenced a slight anxiolytic effect for two new compounds, Q3 and Q5. They 
increased the time spent in the open arms of the maze with 20.74 and 15.61% 
compared with control group. The mean results can be observed in Figure 4.
Also, the same two compounds produced a decrease of the time spent in closed 
arms of the maze, with 5.92 and 4.92% compared with control (Figure 5).
The preference of the animals for the open arms instead of closed ones is a 
sign of lower anxiety, thus we can affirm that compounds Q3 and Q5 have a slight 
anxiolytic effect. The other compounds did not influence the parameters in EPM.
4. Conclusion
We obtained five new 4(3H)-quinazolinone derivatives through a standard-
ized synthesis process. The compounds were characterized by measuring the 
melting points, by determining the infrared and NMR spectra, and by elemental 
analysis.
The pharmacological tests evidenced that the five new quinazolinones have a 
very low acute toxicity, lethal doses being >2000 mg/kg bw.
Regarding the results obtained in pharmacological tests for evaluation of anti-
depressant and anxiolytic effects, the compounds had different actions, probably 
influenced by the presence of different radicals on the nucleus.
Thus, Q1 which have the nitro group in structure manifested the highest antide-
pressant effect, with a reduction of immobilization time in FST with 20.39% and in 
TST with 20.13% compared with control.
On the other hand, compounds Q3 and Q5, with two groups methoxy, respective 
ethoxy, had a slight anxiolytic effect, highlighted by increasing the time spent in 
open arms, with 20.74 and 15.61% compared with control.
The five new compounds have been shown to have central nervous system activ-
ity, and we consider that they deserve further testing in order to detect other effects 
of interest.
Figure 5. 
Time in closed arms of EPM after 15 days of administration (the columns represent the mean + SD).
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